at Zacks.com (Jan 20, 2015)
Novo Nordisk's (NVO -0.2%) Victoza's outperformed Merck's (MRK -0.2%) Januvia and Amylin's (BMY) exenatid BID in patients with type two diabetes. More subjects given Victoza had a blood-sugar level below 7% those who received the rival drugs. (PR)
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Benzinga.com (Jan 14, 2015)
at Investor's Business Daily (Jan 8, 2015)
at CNBC.com (Dec 29, 2014)
at Zacks.com (Dec 24, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs